Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by WORKINMONTANAon Mar 05, 2021 9:49am
94 Views
Post# 32726854

Buzz on the Bullboards: In the COVID Fallout, New Players

Buzz on the Bullboards: In the COVID Fallout, New Players

 


[url=Buzz on the Bullboards: In the COVID Fallout, New Players Emerge]Buzz on the Bullboards: In the COVID Fallout, New Players Emerge[/url]

 

Buzz on the Bullboards: In the COVID Fallout, New Players Emerge


  Stockhouse Editorial
0 Comments| 1 day ago
 

 5



Back in early March 2020, the COVID-19 pandemic was still not much of a concern for the markets. 

While investors were keeping an eye on it, compared to other geopolitical factors at the time, it was mostly an afterthought of little consequence. 

Fast-forward a year and it seems we are still seeing the unraveling effects of the reality of COVID-19. Markets, health services, and politicians continue to struggle, as the pandemic spreads in scope and fear, with none the wiser as to whether the full impact will be relatively calm or worse than expected as new variants emerge. 

But as new strains appear, so to do new plays; some are brand new companies, others have pivoted to capitalize on a variety of solutions the COVID problem has created. 

Sponsored by 
Stockhouse Users Get $20 For Free To Buy Crypto


Investors are shifting their correction investment strategies alongside market selloffs at large. A significant part of this strategy is to stay safe, calm, and diversified, but another key factor for many investors on the Stockhouse Bullboards is to gauge which companies will be able to recover, and when. 

This week, we highlight two sides of the impact the markets have faced so far, by looking at the most-viewed companies in resources, as well as healthcare, specifically cannabis. 

Starting with a look at what is happening in cannabis and the companies operating in and around that market, Kalytera Therapeutics Inc. (TSX-V:KLYForumis now going by the name Claritas Pharmaceuticals, Inc. and this week, the CBD biotech company touted the potential of its proprietary nitric oxide releasing compound, R-107, as a therapy for coronavirus and COVID-19 infection, citing new data by Massachusetts General Hospital. Claritas has concentrated its focus on the development on R-107. The nitric oxide-releasing compound. Following administration orally in a capsule, or by nasal spray, or by injection, R-107 enters the bloodstream, where it slowly releases nitric oxide systemically over 24 hours. 


<< Previous
Bullboard Posts
Next >>